Antibody-Drug Conjugates (ADCs) have shaped how we think about bioconjugation chemistry, CMC strategy, and manufacturing at scale. Now that knowledge is opening up new possibilities for Antibody-Oligonucleotide Conjugate (AOC) development.

On June 17th, our VP of Bioconjugation Development & Technical Excellence, Ian Glassford, will be presenting at the Virtual Outsourced Pharma ADC Capabilities Update, with a session exploring what it takes to build efficient CMC processes for this emerging modality: “Leveraging Advanced ADC Expertise to Design & Deliver Next-Gen AOCs”.

While AOCs build on the same bioconjugation principles as ADCs, oligonucleotide payloads present a distinct set of challenges compared to small molecule cytotoxics. Their differences fundamentally change how conjugation chemistry, linker selection, and analytical characterization need to be approached.

Ian will walk through how Abzena’s conjugation platforms are being adapted for AOC development and give real-world examples of how these programs come together from Fab intermediate development through GMP manufacture.

If AOCs are part of your drug development pipeline, we hope you join us.

Register Here